NWI Management LP Takes $35.38 Million Position in Becton, Dickinson and Company $BDX

Key Points

• NWI Management LP acquired 225,000 shares of Becton, Dickinson and Company during the first quarter, valued at approximately $35.38 million and representing about 2% of the firm’s portfolio.
• BDX reported quarterly earnings of $2.90 per share, exceeding estimates of $2.77, while revenue rose 5.2% year over year to $4.71 billion. The company reaffirmed fiscal 2026 EPS guidance of $12.52–$12.72.
• The stock has a consensus “Hold” rating and an average analyst price target of $180.93; BDX also declared a quarterly dividend of $1.05 per share, implying a 2.5% annualized yield.

NWI Management LP bought a new position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor bought 225,000 shares of the medical instruments supplier's stock, valued at approximately $35,377,000. Becton, Dickinson and Company accounts for about 2.0% of NWI Management LP's holdings, making the stock its 13th largest position. NWI Management LP owned about 0.08% of Becton, Dickinson and Company at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in BDX. Auto Owners Insurance Co increased its position in shares of Becton, Dickinson and Company by 22,225.2% during the fourth quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier's stock worth $790,079,000 after acquiring an additional 40,528,680 shares during the period. Vanguard Group Inc. boosted its holdings in Becton, Dickinson and Company by 13.0% in the fourth quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier's stock valued at $7,118,282,000 after purchasing an additional 4,223,149 shares during the period. State Street Corp grew its stake in Becton, Dickinson and Company by 0.8% during the 4th quarter. State Street Corp now owns 13,989,132 shares of the medical instruments supplier's stock worth $2,714,871,000 after purchasing an additional 116,737 shares in the last quarter. First Eagle Investment Management LLC grew its stake in Becton, Dickinson and Company by 16.5% during the 4th quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier's stock worth $2,260,139,000 after purchasing an additional 1,651,592 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA increased its holdings in Becton, Dickinson and Company by 3.7% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 9,486,694 shares of the medical instruments supplier's stock worth $1,841,083,000 after purchasing an additional 336,110 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the sale, the executive vice president directly owned 13,172 shares in the company, valued at $1,918,633.52. This trade represents a 7.71% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the business's stock in a transaction on Monday, June 1st. The shares were sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the sale, the chief executive officer directly owned 110,163 shares of the company's stock, valued at approximately $16,122,355.05. This trade represents a 2.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 5,189 shares of company stock valued at $765,661 in the last 90 days. Insiders own 0.40% of the company's stock.

Becton, Dickinson and Company Trading Up 0.4%

NYSE:BDX opened at $166.19 on Friday. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35. The stock has a market cap of $45.79 billion, a P/E ratio of 42.07, a P/E/G ratio of 11.80 and a beta of 0.21. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.94. The stock has a 50-day simple moving average of $151.85 and a 200-day simple moving average of $163.64.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.13. The business had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The business's quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter last year, the company earned $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, analysts anticipate that Becton, Dickinson and Company will post 12.53 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.5%. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 106.33%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on BDX shares. Bank of America reduced their price target on Becton, Dickinson and Company from $177.00 to $170.00 in a research report on Friday, June 12th. Barclays upped their target price on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an "overweight" rating in a research note on Monday, May 11th. Wells Fargo & Company raised their target price on shares of Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an "equal weight" rating in a report on Friday, May 8th. Weiss Ratings downgraded shares of Becton, Dickinson and Company from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Monday, May 11th. Finally, The Goldman Sachs Group lowered their price target on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a "neutral" rating for the company in a report on Wednesday, May 27th. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of "Hold" and a consensus price target of $180.93.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.